Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
1:1:1 Blood Transfusion Ratio · 1 trial · 1 indication
Blood samples were collected at time of ED admission and over time to determine the incidence of reported venous thrombolic events (VTE).
| Arm | Type | Description |
|---|---|---|
| 1:1:1 Blood Transfusion Ratio | ACTIVE_COMPARATOR | - |
| 1:1:2 Blood Transfusion Ratio | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| 1:1:1 Blood Transfusion Ratio | BIOLOGICAL | Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol. |
| 1:1:2 Blood Transfusion Ratio | BIOLOGICAL | Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol. |
Inclusion Criteria: * Subjects who require the highest trauma team activation at each participating center, * Estimated age of 15 years or older or greater than/equal to weight of 50 kg if age unknown, * Received directly from the injury scene, * Initiated transfusion of at least one unit of blood ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | - | Undisclosed |
| Bone Biologics Corp. | BBLG | 1 | - | Undisclosed |
The 1:1:1 Blood Transfusion Ratio is a transfusion strategy being studied for use in trauma patients. It involves administering platelets, plasma, and red blood cells in equal ratios to manage severe bleeding. The approach is under investigation as a treatment for trauma-related hemorrhage.
The 1:1:1 Blood Transfusion Ratio is being developed by United Therapeutics Corporation, a company traded on the NASDAQ under the ticker UTHR. The company is conducting clinical research to evaluate this transfusion strategy in trauma patients.
The 1:1:1 Blood Transfusion Ratio is in Phase 3 clinical development. It is an investigational transfusion strategy, not yet approved by regulatory authorities. The Phase 3 trial has been completed, and the strategy remains under clinical investigation for trauma.
The 1:1:1 Blood Transfusion Ratio was evaluated in a Phase 3 clinical trial registered as NCT01545232, titled 'Pragmatic, Randomized Optimal Platelet and Plasma Ratios.' This completed trial enrolled 680 participants with trauma in the United States and Canada.
Yes, the 1:1:1 Blood Transfusion Ratio was studied in a randomized, active-controlled clinical trial. The trial was not double-blinded, and it compared the 1:1:1 ratio strategy against an active control. The study enrolled 680 trauma patients and has been completed.